As already shown for a larger patient cohort (30), also in a subgroup of non-metastasized NSCLC patients, high pre-therapeutic OPN plasma levels (above median, n = 22) significantly correlated with inferior OS compared to low (below median, n = 22) levels (13 [5–66] vs. 23 [5–61]; p < 0.05). The gene discussed is SPP1; the disease is non-small cell lung carcinoma.